Akari Therapeutics, Plc (AKTX) is a biopharmaceutical company focused on developing therapies for the treatment of inflammatory diseases and autoimmune disorders. The company's main focus is on researching and developing complement inhibition-based therapies, which play a key role in the body's immune response. One of the company's main products is Nomacopan (also known as Coversin), which is being developed for the treatment of various diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and other autoimmune disorders. Akari Therapeutics, Plc aims to bring innovative therapeutic solutions to patients with diseases that have not been adequately addressed by existing treatments. Shares of Akari Therapeutics, Plc (AKTX) could be suitable for investors who are tracking the biotechnology sector and seeking opportunities in the development of drugs for inflammatory diseases and autoimmune disorders.
Feed
There are no posts to show right now.
Używamy ciasteczek, aby ulepszyć Twoje doświadczenie na naszej stronie.
